Sep 20, 2024 · Researchers are exploring a variety of vaccine approaches that are showing promise in prostate cancer, which has historically been a difficult malignancy to target with vaccines and other immunotherapies.

Immunotherapy is the use of medicines to stimulate a person’s own immune system to recognize and destroy cancer cells more effectively. Certain types of immunotherapy can be used to treat prostate cancer. Sipuleucel-T (Provenge) is a cancer vaccine.

May 10, 2024 · One of the earliest immunotherapies approved by the Food and Drug Administration (FDA) for the treatment of cancer was a vaccine called sipuleucel-T. It’s been used to treat metastatic prostate cancer since 2010.

Immunotherapy for prostate cancer works by helping a patient’s own immune system fight back against cancer cells. One immune therapy that has been approved by the FDA is a vaccine called sipuleucel-T (Provenge), which spurs a patient’s immune system to attack prostate cancer cells.

Recently, several promising vaccines have been developed for prostate cancer treatment, such as Prostvac, Provenge (Sipuleucel-T) and individualized PPV (polypeptide vaccine). Provenge is the only cellular active immune product licensed by FDA to …

May 27, 2024 · Cancer vaccines and checkpoint inhibitors are approved immunotherapies for prostate cancer. CAR T-cell therapy is a new treatment that doctors are learning more about in clinical trials .

Mar 6, 2023 · For over 30 years, growing interest has focused on the development of vaccines as treatments for prostate cancer, with the goal of using vaccines to activate immune cells capable of...

Provenge is the first therapeutic cancer vaccine to receive approval from the U.S. FDA. For patients with advanced prostate cancer, Provenge (sipuleucel-T) is an immunotherapy treatment that utilizes the power of the patient’s own immune system to …

With a cancer vaccine and checkpoint inhibitor approved, immunotherapy for prostate cancer offers new hope to patients with advanced prostate cancer.

For over 30 years, growing interest has focused on the development of vaccines as treatments for prostate cancer, with the goal of using vaccines to activate immune cells capable of targeting prostate cancer to either eradicate recurrent disease or at least delay disease progression.